Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants

Biochemical Pharmacology

Volumn 76, Issue 4, 2008, Pages 476-481

  Ahlstedt, Ingela ^a   Engberg, Susanna ^a   Smith, John ^b   Perrey, Chris ^b   Moody, Adrian ^b   Morten, John ^b   Lagerström Fermér, Maria ^a   Drmota, Tomas ^a   von Mentzer, Bengt ^a   Påhlman, Ingrid ^a   Lindström, Erik ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Neurokinin A; Polymorphism; Saredutant; Tachykinin receptor antagonist; ZD6021

Indexed keywords

ARGININE; CALCIUM ION; HISTIDINE; ISOLEUCINE; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; SAREDUTANT; THREONINE; UNCLASSIFIED DRUG; ZD 6021;

ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; GENE FREQUENCY; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ANIMALS; CALCIUM SIGNALING; CHO CELLS; CRICETINAE; CRICETULUS; GENE FREQUENCY; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NEUROKININ-2; RECEPTORS, TACHYKININ; TRANSFECTION; VARIATION (GENETICS);

EID: 48349128039     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.003     Document Type: Article

References (44)

1. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharm Rev 54 (2002) 285-322
2. Maggi C.A. The mammalian tachykinin receptors. Gen Pharmacol 26 (1995) 911-944
3. Edgerton M.D., Chabert C., Chollet A., and Arkinstall S. Palmitoylation but not the extreme amino-terminus of Gq alpha is required for coupling to the NK2 receptor. FEBS Lett 354 (1994) 195-199
4. Catalioto R.M., Cucchi P., Renzetti A.R., Criscuoli M., and Maggi C.A. Independent coupling of the human tachykinin NK2 receptor to phospholipases C and A2 in transfected Chinese hamster ovary cells. Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 395-403
5. Nakajima Y., Tsuchida K., Negishi M., Ito S., and Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 267 (1992) 2437-2442
6. Blount P., and Krause J.E. Functional nonequivalence of structurally homologous domains of neurokinin-1 and neurokinin-2 type tachykinin receptors. J Biol Chem 268 (1993) 16388-16395
7. Palanche T., Ilien B., Zoffmann S., Reck M.P., Bucher B., Edelstein S.J., et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 276 (2001) 34853-34861
8. Lecat S., Bucher B., Mely Y., and Galzi J.L. Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J Biol Chem 277 (2002) 42034-42048
9. Portbury A.L., Furness J.B., Southwell B.R., Wong H., Walsh J.H., and Bunnett N.W. Distribution of neurokinin-2 receptors in the guinea-pig gastrointestinal tract. Cell Tissue Res 286 (1996) 281-292
10. Lecci A., Giuliani S., Tramontana F., Carini F., and Maggi C.A. Peripheral actions of tachykinins. Neuropeptides 34 (2000) 303-313
11. Strigas J., and Burcher E. Autoradiographic localization of tachykinin NK2 and NK1 receptors in the guinea-pig lung, using selective radioligands. Eur J Pharmacol 311 (1996) 177-186
12. Patak E.N., Pennefather J.N., and Story M.E. Effects of tachykinins on uterine smooth muscle. Clin Exp Pharmacol Physiol 27 (2000) 922-927
13. Joos G.F. The role of neuroeffector mechanisms in the pathogenesis of asthma. Curr Allergy Asthma Rep 1 (2001) 134-143
14. Lecci A., Santicioli P., and Maggi C.A. Pharmacology of transmission to gastrointestinal muscle. Curr Opin Pharmacol 6 (2002) 630-641
15. Lecci A., Capriati A., and Maggi C.A. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 141 (2004) 1249-1263
16. Bensaid M., Faucheux B.A., Hirsch E., Agid Y., Soubrie P., and Oury-Donat F. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 303 (2001) 25-28
17. Saffroy M., Torrens Y., Glowinski J., and Beaujouan J.C. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 116 (2003) 761-773
18. Steinberg R., Alonso R., Griebel G., Bert L., Jung M., Oury-Donat F., et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299 (2001) 449-458
19. Salome N., Stemmelin J., Cohen C., and Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 83 (2006) 533-539
20. Dableh L.J., Yashpal K., Rochford J., and Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507 (2005) 99-105
21. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., and Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 89 (2008) 36-45
22. Quartara L., and Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 7 (2006) 975-992
23. Tang C.M., and Insel P.A. Genetic variation in G-protein-coupled receptors-consequences for G-protein-coupled receptors as drug targets. Expert Opin Ther Targets 9 (2005) 1247-1265
24. Randolph G.P., Simon J.S., Arreaza M.G., Qiu P., Lachowicz J.E., and Duffy R.A. Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant. Pharmacogen J 4 (2004) 394-402
25. Fong T.M., Yu H., and Strader C.D. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonist CP-96,345. J Biol Chem 267 (1992) 25668-25671
26. Engberg S., Ahlstedt A., Leffler A., Lindström E., Kristensson E., Svensson A., et al. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors. Biochem Pharmacol 73 (2007) 259-269
27. Gordon D., Abajian C., Green P., and Consed:. A graphical tool for sequence finishing. Genome Res 8 (1998) 195-202
28. Graham A., Hopkins B., Powell S.J., Danks P., and Briggs I. Isolation and characterisation of the human lung NK-2 receptor gene using rapid amplification of cDNA ends. Biochem Biophys Res Commun 177 (1991) 8-16
29. 2 antagonists. Bioorg Med Chem Lett 11 (2001) 2769-2773
30. Advenier C., Rouissi N., Nguyen Q.T., Emonds-Alt X., Breliere J.C., Neliat G., et al. Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun 184 (1992) 1418-1424
31. i) and the concentration inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
32. Gerard N.P., Eddy Jr. R.L., Shows T.B., and Gerard C. The human neurokinin A (substance K) receptor. J Biol Chem 265 (1990) 20455-20462
33. Kris R.M., South V., Saltzman A., Felder S., Ricca G.A., Jaye M., et al. Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. Cell Growth Diff 2 (1991) 15-22
34. Huang R.-R., Vicario P.P., Strader C.D., and Fong T.M. Identification of residues involved in ligand binding to the neurokinin-2 receptor. Biochemistry 34 (1995) 10048-10055
35. Bhogal N., Donnelly D., and Findlay J.B. The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor. J Biol Chem 269 (1994) 27269-27274
36. Labrou N.E., Bhogal N., Hurrell C.R., and Findlay J.B.C. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. J Biol Chem 276 (2001) 37944-37949
37. Zoffmann S., Bertrand S., Do Q.-T., Bertrand D., Rognan D., Hibert M., et al. Topographical analysis of the complex formed between neurokinin A and the NK2 tachykinin receptor. J Neurochem 101 (2007) 506-516
38. Renzetti A.R., Catalioto R.M., Carloni C., Criscuoli M., Cucchi P., Giolitti A., et al. Defects of tyrosine 289 phenylalanine mutation on binding and functional properties of the human tachykinin NK2 receptor stably expressed in Chinese hamster ovary cells. Biochem Pharmacol 57 (1999) 899-906
39. Giolitti A., Cucchi P., Renzetti A.R., Rotondaro L., Zappaletti S., and Maggi C.A. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis. Neuropharmacology 39 (2000) 1422-1429
40. Copeland R.A., Pompliano D.L., and Meek T.D. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5 (2006) 730-739
41. 2 receptor antagonist activity. J Med Chem 45 (2002) 3972-3983
42. Candenas M.L., Cintado C.G., Pennefather J.N., Pereda M.T., Loizaga J.M., Maggi C.A., et al. Identification of a tachykinin NK(2) receptor splice variant and its expression in human and rat tissues. Life Sci 72 (2002) 269-277
43. Bellucci F., Meini S., Catalioto R.-M., Catalani C., Giuliani S., Quartara L., et al. Pharmacological evaluation of α and β human tachykinin NK2 receptor splice variants expressed in CHO cells. Eur J Pharmacol 499 (2004) 229-238
44. Park H.-K., Oh S.-Y., Kim T.-B., Bahn J.-W., Shin E.-S., Lee J.-E., et al. Association of genetic variations in neurokinin-2 receptor with enhanced cough sensitivity to capsaicin in chronic cough. Thorax 61 (2006) 1070-1075